BMT CTN 1507 儿童镰状细胞病单倍体移植试验的递增入组标准
BMT CTN 1507 是一项针对5至14.99岁镰状细胞病儿童的2期HLA单倍体造血干细胞移植试验,其领导层与数据安全监查委员会(DSMB)建立了递增入组标准。首10例仅限明显卒中(4期),后经DSMB审查中期结果扩大至静默脑梗死或经磁共振血管成像定义脑血管病的异常经颅多普勒流速(3期),再经DSMB审查累计初始入组18例的临床结局后增加非神经性并发症标准(2期)。不符合4、3、2期标准者不符合入组条件。
要点
- 首10例仅限明显卒中(4期),后扩大至静默脑梗死或脑血管病(3期)。
- DSMB审查累计初始入组18例后增加非神经性并发症标准(2期)。
- 增加的2期标准包括需换血治疗的危及生命急性胸综合征等5项。
核心结论
- 据我们所知,首次在镰状细胞病儿童治愈性治疗试验中引入与45 Code of Federal Regulations § 46.405(b)一致的递增入组策略。
- BMT CTN 1507 2期研究中由研究治理 mandated 的入组策略可能适用于未来儿童镰状细胞病治愈性治疗试验。
研究设计与样本
- BMT CTN 1507 是一项针对5至14.99岁镰状细胞病儿童的2期HLA单倍体造血干细胞移植试验。
- 由BMT CTN 1507领导层与数据安全监查委员会(DSMB)建立递增入组标准。
- 试验注册于www.ClinicalTrials.gov,编号#NCT032635590。
主要发现
- 首10例入组仅限明显卒中(4期)。
- DSMB审查中期结果后,将入组扩大至静默脑梗死或经磁共振血管成像定义脑血管病的异常经颅多普勒流速(3期)。
- DSMB审查累计初始入组18例的临床结局后,增加非神经性并发症标准(2期)。
关键数值与推荐
- 4期:首10例仅限明显卒中。
- 3期:静默脑梗死或经磁共振血管成像定义脑血管病的异常经颅多普勒流速。
- 2期增加标准包括:(1)需换血治疗的危及生命急性胸综合征;(2)右心导管确认的肺动脉高压;(3)尽管最大药物治疗仍持续的系统性高血压;(4)在无心理社会因素且未控制的哮喘经裁定后,尽管最大药物治疗仍急性疼痛;(5)12个月内2次或24个月内3次主要阴茎异常勃起。
- 不符合4、3、2期标准者不符合入组条件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1507 leadership and the data safety monitoring board (DSMB) established incremental entry criteria for children aged 5 to 14.99 years with sickle cell disease (SCD) enrolling in a phase 2 trial of HLA-haploidentical hematopoietic stem cell transplantation. First, the enrollment was limited to overt stroke in the first 10 participants (stage 4). Subsequently, the DSMB reviewed the interim results and expanded the eligibility to include children with silent cerebral infarcts or abnormal transcranial Doppler velocities with magnetic resonance angiography-defined cerebral vasculopathy (stage 3). A third cohort was enrolled after the DSMB reviewed the clinical outcomes in these cumulative initial enrollments (n = 18) and additions were made to the entry criteria that included nonneurologic morbidities (stage 2). Added eligibility criteria included the following: (1) life-threatening acute chest syndrome requiring exchange transfusion; (2) right heart catheterization confirmed pulmonary hypertension; (3) persistent systemic hypertension despite maximum medical therapy; (4) acute pain despite maximum medical therapy in the absence of psychosocial factors and unmanaged asthma after adjudication; and (5) 2 major priapism episodes in 12 months or 3 in 24 months. Children with SCD who did not meet the criteria for stages 4, 3, and 2 were not eligible. To our knowledge, for the first time, we introduce a staged strategy for eligibility in a curative therapy trial for children with SCD concordant with 45 Code of Federal Regulations § 46.405(b). The research governance-mandated eligibility strategy used within the BMT CTN 1507 phase 2 study may apply to future pediatric SCD curative therapy trials. This trial was registered at www.ClinicalTrials.gov as #NCT032635590.
引用
- John TD, Walters MC, Rangarajan HG, et al. Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease. Blood Adv. 2024. PMID: 39374573. doi:10.1182/bloodadvances.2024014078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。